ALACHUA, Fla., June 9, 2014 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (Nasdaq: AXGN ), a leading medical technology company focused on the $1.6 billion US peripheral nerve repair market, is scheduled to present at the 9th Annual JMP Securities Healthcare Conference on Tuesday, June 24, 2014 at 12:30pm (ET) at the Westin New York Grand Central.
A live webcast and subsequent archived replay of the Company's presentation may be accessed via the Investors section of the Company's website at http://ir.axogeninc.com/ .
About AxoGen, Inc.
AxoGen (Nasdaq: AXGN ) is a leading medical technology company dedicated to peripheral nerve repair. AxoGen's portfolio of regenerative medicine products is available in the United States, Canada and several European countries and includes Avance® Nerve Graft, the only off-the-shelf commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix ("ECM") coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.
Avance® Nerve Graft is processed in the United States by AxoGen. AxoGuard® Nerve Connector and AxoGuard® Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, and are distributed exclusively by AxoGen. AxoGen maintains its corporate offices in Alachua, Florida and is the parent of its wholly owned operating subsidiary, AxoGen Corporation. To receive email alerts directly from AxoGen, please click here http://www.axogeninc.com/emailalerts.html .
Source: AxoGen, Inc.
This article was originally distributed on PRWeb. For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2014/06/prweb11920078.htm
AxoGen, Inc. Lee Robert "Bob" Johnston Jr, CFO +1 612.619.6324
